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Objective
To evaluate the potential of isolated limb perfusion (ILP) for
efficient and tumor-specific adenovirus-mediated gene trans-
fer in sarcoma-bearing rats.
Summary Background Data
A major concern in adenovirus-mediated gene therapy in can-
cer is the transfer of genes to organs other than the tumor,
especially organs with a rapid cell turnover. Adjustment of the
vector delivery route might be an option creating tumor speci-
ficity in therapeutic gene expression.
Methods
Rat hind limb sarcomas (5–10 mm) were transfected with re-
combinant adenoviruses. Intratumoral luciferase expression
after ILP was compared with systemic administration, regional
infusion, or intratumoral injection using a similar dose of ad-
enoviruses carrying the luciferase marker gene. Localization
studies using lacZ as a marker gene were performed to evalu-
ate the intratumoral distribution of transfected cells after both
ILP and intratumoral injection.
Results
Intratumoral luciferase activity after ILP or intratumoral admin-
istration was significantly higher compared with regional infu-
sion or systemic administration. After ILP, luciferase gene ex-
pression was minimal in extratumoral organs, whether outside
or inside the isolated circuit. Localization studies demon-
strated that transfection was confined to tumor cells lying
along the needle track after intratumoral injection, whereas
after ILP, lacZ expression was found in viable tumor cells and
in the tumor-associated vasculature.
Conclusions
Using ILP, efficient and tumor-specific gene transfection can
be achieved. The ILP technique might be useful for the deliv-
ery of recombinant adenoviruses carrying therapeutic gene
constructs to enhance tumor control.
Recent advances in molecular engineering have enabled
gene therapy to become a promising therapeutic entity for
an ever-increasing number of clinical applications. Of the
potential viral and nonviral vector systems for the transfer
of therapeutic genes into target cells, recombinant retrovi-
ruses and adenoviruses have been most widely used in both
preclinical studies and clinical trials.1 Virus-mediated gene
transfer can be accomplished by either ex vivo or in vivo
approaches. The ex vivo strategy involves harvesting the
target cells, genetically modifying them in vitro, and reim-
planting them into the patient. The in vivo approach in-
volves the direct transfection of target cells by recombinant
viruses with transgene, using systemic, regional, or tissue-
specific administration.2
Although gene therapy was originally developed for cor-
rection of genetic deficiencies of inherited disorders of
metabolism, current interest is mainly focused on its poten-
tial therapeutic roles in cardiovascular disease and cancer.
Approaches to cancer gene therapy include genetic mark-
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ing, cancer vaccination, inhibition of oncogene expression,
restoration of tumor suppressor genes, and the use of suicide
genes, which may be one of the most successful therapeutic
strategies to date. The suicide gene strategy aims at the
induction of drug sensitivity by introducing genes such as
the herpes simplex thymidine kinase gene into the tumor
cells, whose expression initiates the formation of prodrug
metabolizing enzymes. The herpes simplex thymidine ki-
nase gene converts ganciclovir into phosphorylated metab-
olites that act as chain terminators during DNA synthesis, in
this way causing selective cell death.3,4
A major concern in the enzyme/prodrug approach is the
transfer of suicide genes to organs other than the tumor,
especially organs with a rapid cell turnover. The risk of
infecting cell types other than target cells is negligible in
strategies involving the ex vivo suicide gene transfer.5,6
However, apart from a possible role in cancer vaccination,
ex vivo gene transfer is clearly not applicable in anticancer
gene therapy. In vivo gene delivery, in contrast, should be
targeted to tumor cells to avoid complications resulting
from leakage of genes to other cells in the body. One way
to achieve tumor-specific in vivo gene delivery is by tissue-
specific administration of viral vectors to tumor cells.2
In surgical oncology trials, isolated limb perfusion (ILP)
is successfully used for administration of chemotherapeutic
agents and cytokines to locally advanced soft tissue extrem-
ity sarcomas and in-transit melanoma metastases.7–10 ILP
involves the recirculation of high drug concentrations in a
vascularly isolated extremity, resulting in minimal drug
exposure to organs outside the closed circuit. In the present
study, we evaluated the efficiency and tumor specificity of
adenovirus-mediated gene transfer using ILP in an estab-
lished sarcoma-bearing rat model.11–13 We quantified the
activity of a marker gene in limb sarcomas after ILP with
adenoviral vectors carrying the luciferase marker gene. The
intratumoral luciferase gene expression was compared with
the luciferase activity in other organs either inside or outside
the isolated vascular circuit. The efficiency and tumor spec-
ificity of ILP-mediated gene transfer was compared with
other delivery routes, including systemic administration,
regional infusion, and intratumoral injection. Moreover, ad-
enoviral vectors carrying the lacZ marker gene were used to
determine the intratumoral localization of transfected cells
after both ILP and intratumoral administration.
METHODS
Adenoviral Vectors
All adenoviral vectors used in this study were derived
from human adenovirus type 5 and were deleted for the El
region in which the transgenes were cloned. The E3 region
was retained in all vectors. The cytomegalovirus (CMV)
promoter and adenoviral major late promoter (MLP) were
used to drive the lacZ and luciferase marker genes. The
construction and production of IG.Ad.MLP.Luc, IG.Ad.
CMV.Luc, and IG.Ad.CMV.LacZ recombinant adenovi-
ruses is described in detail elsewhere.14 Briefly, recombi-
nant adenoviral vectors were plaque-purified twice,
propagated on 293 or PER.C6 cells, purified by CsCl den-
sity centrifugation, dialyzed, and stored at 280°C in buffer
containing (in mmol/L) 13 Na2HPO4 (pH 7.4), 140 NaCl,
0.9 CaCl2, and 0.5 MgCl2 and 5% (m/v) sucrose. The virus
titers (infectious units [iu]/mL) were determined by end-
point cytopathogenic effect titrations using 911 cells.4 All
recombinant adenoviral vectors were produced at Intro-
Gene, Leiden, The Netherlands.
Animals
Inbred male Brown Norway rats and WagRij rats, weigh-
ing 200 to 300 g, were obtained from Harlan (Zeist, The
Netherlands). Animals were kept in standard laboratory
conditions and were fed a standard laboratory diet (Hope
Farms, Woerden, The Netherlands). The experimental pro-
tocols adhered to the rules described in the Dutch Animal
Experimentation Act and the Guidelines on the Protection
of Experimental Animals by the Council of the European
Community. Before the experiments, the protocols were
approved by the Animal Research Committee of Erasmus
University in Rotterdam and of the University of Leiden,
The Netherlands.
Tumor Model
The spontaneous BN-175 sarcoma and ROS-1 osteosar-
comas were implanted in the flank of donors and passaged
serially. Both tumors are nonimmunogenic and rapidly
growing and metastasizing, with a doubling time of approx-
imately 5 to 7 days.15 Small tumor fragments were subcu-
taneously implanted into the right hind limb just above the
ankle. All surgical interventions were performed at a tumor
diameter of 5 to 10 mm, at least 7 days after implantation.
Administration Techniques
All surgical procedures were performed under Hypnorm
anesthesia (Janssen Pharmaceutica, Tilburg, The Nether-
lands). For ILP, we used the technique described by
Manusama et al11 (Fig. 1). Briefly, the femoral vessels were
approached through an incision parallel to the inguinal
ligament after systemic heparin administration (50 IU).
Subsequently, the femoral artery and vein were cannulated
with Silastic tubing (0.30 mm inner diameter, 0.64 mm
outer diameter; 0.64 mm inner diameter, 1.19 mm outer
diameter, respectively; Dow Corning, Ann Arbor, MI). Col-
laterals were temporarily occluded by applying a tourniquet
around the groin. Perfusion was performed with recombi-
nant adenoviral vectors (1 3 109 iu IG.Ad.MLP.Luc or 1 3
109 iu IG.Ad.CMV.LacZ) added as a bolus in 5 mL
Haemaccel (Behring Pharma, Amsterdam, The Nether-
lands). An oxygenation reservoir and a roller pump were
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included in the isolated circuit. The perfusate was circulated
at a flow speed of 2 mL per minute for 5 to 30 minutes.
After ILP, the isolated circuit was perfused with Haemaccel
for another 5 minutes to wash out the nonbound viruses.
During ILP and washout, the hind leg was kept at a constant
temperature of 38° to 39°C by a warm-water mattress ap-
plied around the leg. After washout, the isolated circuit was
discontinued, and after tube removal the femoral vessels
were ligated. Previous experiments have shown that the
collateral circulation to the leg is so extensive that ligation
of the femoral vessels can be performed without detrimental
effects.11
For intratumoral injection, the same amount of recombi-
nant adenoviral vectors (1 3 109 iu IG.Ad.MLP.Luc or 1 3
109 iu IG.Ad.CMV.LacZ) was injected into the center of the
BN-175 tumor using a 25-gauge needle. Leakage of virus
was minimized by tamponade of the injection site with a
cotton tip. For systemic administration, adenoviral vectors
(1 3 109 iu IG.Ad.MLP.Luc or 1 3 109 iu IG.Ad.CMV.
Luc) were injected into the penile vein using a 25-gauge
needle, followed by tamponade to prevent virus and blood
leakage. For regional administration, a Silastic tube (0.30
mm inner diameter, 0.64 mm outer diameter) was implanted
into the femoral artery. Recombinant adenoviruses (1 3 109
iu IG.Ad.MLP.Luc), dissolved in 1 mL Haemaccel, were
infused through the implanted tube, followed by 1 mL
Haemaccel to wash out the adenoviral vectors from the
Silastic tube. Also in these animals, the femoral artery was
ligated after tube removal.
Luciferase Assay
Two days after administration of luciferase, the experi-
mental animals were killed. Tumor and quadriceps muscle
in the isolated circuit were removed. In addition, liver,
spleen, heart, lung, kidney, intestine, gonads, and aorta, all
outside the isolated limb, were harvested for measurement
of luciferase activity. Cross-contamination of the tissue
samples was avoided by cleaning the equipment thoroughly
with 1% SDS, H2O, and ethanol after dissection of each
sample. Removed tissues were weighed, frozen in liquid N2,
and stored at 220°C. Later, samples were thawed in 2 mL
ice-cold lysis buffer (8 mmol/L MgCl2, 1 mmol/L EDTA, 1
mmol/L DTT, 1% Triton X-100, and 15% glycerol in phos-
phate-buffered saline [PBS]) then homogenized. Lysed cells
were collected and centrifuged (14,000 rpm for 7 minutes)
at 2° to 6°C to remove cell debris. Luciferase activity
present in 20 mL lysate was determined by adding 100 mL
of luciferase assay reagent (Promega, Madison, WI). After
10 seconds of preincubation, the produced light was mea-
sured for 30 seconds in a Lumat LB9501 luminometer
(Berthold, Wildbad, Germany). Protein concentrations of
different tissues were determined using the Biorad Protein
Assay kit (Biorad, Mu¨nchen, Germany), and luciferase ac-
tivity was calculated as relative light units per milligram
protein.
b-Galactosidase Histochemistry
Two days after ILP or intratumoral injection, the exper-
imental animals exposed to Ad.CMV.LacZ were killed and
the tumor was dissected. Tumor tissues were fixed for 1
hour in ice-cold 2% paraformaldehyde/0.25% glutaralde-
hyde solution. After fixation, the tissues were washed with
PBS and incubated for 1 day in freshly prepared X-gal
staining solution (Boehringer, Mannheim, Germany). The
tissue was washed again with PBS and fixed in 10% buff-
ered formalin solution (40 g NaH2PO4, 81.5 g NaH2PO4,
and 1 L 100% formalin in 10 L demineralized H20). Sub-
sequently, histologic slices were prepared for qualitative
analysis.
Statistical Analysis
The Mann-Whitney test was used to compare luciferase
activity in the various organs after different routes of ad-
ministration.
RESULTS
Optimal Duration of ILP Using
Recombinant Adenoviral Vectors
To determine the optimal duration of ILP for maximal
gene transfer into tumor tissue, luciferase activity was de-
termined and compared after 5, 15, or 30 minutes of perfu-
sion with 1 3 109 iu IG.Ad.MLP.Luc. As shown in Figure
Figure 1. Isolated limb perfusion setting in the rat: a, BN-175 soft
tissue sarcoma; b, perfusion reservoir; c, roller pump; d, oxygenation of
the perfusate; e, tourniquet. (Adapted from ten Hagen, Eggermont. Adv
Drug Deliv Rev 1997; 24:245–256.)
816 de Roos and Others Ann. Surg. c December 2000
2, luciferase activity in tumor tissue increased with longer
perfusion times. However, increments in luciferase gene
expression tended to decrease with longer perfusion times.
There was no increase in luciferase activity in tumor tissue
after 30 minutes of ILP versus 15 minutes (P 5 1.0);
therefore, 15 minutes was used for further experiments.
Systemic leakage of adenoviral vectors to other organs did
not increase with longer perfusions (data not shown).
Efficiency of Gene Transfer in Tumor
Tissue Using Different Administration
Methods
The efficiency of luciferase gene transfer in tumors after
15 minutes of perfusion with 1 3 109 iu IG.Ad.MLP.Luc in
an isolated limb was compared with systemic, regional, and
intratumoral administration with the same amount of recom-
binant adenovirus (Fig. 3). Both ILP and intratumoral in-
jections resulted in a significantly greater mean intratumoral
luciferase activity compared with systemic administration
(both P , .005) and regional infusion (both P , .005).
Intratumoral injection resulted in greater gene expression in
tumor tissue compared with ILP, but the difference was not
significant (P 5 .7). In the intratumoral group, a larger
standard error of the mean (SEM) was observed than in the
other routes of administration, indicating a large variance in
gene transfer between the different injections of adenoviral
vectors in the tumor.
Systemic Leakage of Adenoviral Vectors
Luciferase activity after ILP was measured in various
organs outside and inside the isolated circuit during perfu-
sion with 1 3 109 iu IG.Ad.MLP.Luc. Figure 4 shows
negligible luciferase activity in organs outside the isolated
circuit. Luciferase gene expression fluctuated around the
detection level (100 relative light units per milligram pro-
tein), indicating that the isolated limb perfusion was leak-
age-free. Mean luciferase activity in the tumor was signif-
icantly greater (P , .005) than its activity in quadriceps
muscles, suggesting a preference for tumor cell transfection
in the isolated limb.
Distribution of Adenoviral Vectors After
Systemic Administration
Luciferase activity was measured in various organs after
systemic administration of 1 3 109 iu IG.Ad.CMV.Luc in
WagRij rats bearing a ROS-1 osteosarcoma (Fig. 5). The
CMV promoter was stronger than the MLP promoter, and
thus absolute luciferase gene expression was greater. Much
greater luciferase activity was demonstrated in spleen and
liver, with some activity in tumor tissue comparable to heart
and lung. The muscle of the hind limb and kidney showed
negligible luciferase activity.
Intratumoral Location of Transfected
Marker Genes
Animals underwent ILP (n 5 6) or intratumoral (n 5 6)
administration of 1 3 109 iu IG.Ad.CMV.LacZ and were
Figure 3. Efficacy of gene transfer in BN-175 tumors after administra-
tion of 1 3 109 infectious units IG.Ad.MLP.Luc using isolated limb
perfusion (ILP, n 5 6), intratumoral injection (IT, n 5 6), regional admin-
istration (REG, n 5 6), or systemic administration (SYS, n 5 6). Mean
luciferase activity (6SEM) 48 hours after ILP and IT administration was
significantly different from SYS (both P , .005) and REG administration
(both P , .005).
Figure 4. Organ specificity of gene delivery 48 hours after isolated limb
perfusion using 1 3 109 infectious units IG.Ad.MLP.Luc (n 5 6). Mean
luciferase activity (6SEM) was significantly greater in tumor tissue than
in all other organs inside or outside the isolated circuit (P , .005).
Figure 2. Mean luciferase activity (6SEM) in BN-175 tumors 48 hours
after adenovirus-mediated gene transfer using isolated limb perfusion.
Limbs were perfused with 1 3 109 infectious units IG.Ad.MLP.Luc for 5
minutes (n 5 6), 15 minutes (n 5 6), or 30 minutes (n 5 6).
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killed after 48 hours. Tumors were harvested and histologic
slides were prepared with staining for 13-galactosidase. In
these slides (three per tumor), lacZ-positive cells were iden-
tified and analyzed for cell type and location in the tumor.
After intratumoral administration, lacZ-positive cells were
found along the needle track, without staining tumor cells in
other parts of the tumor (Fig. 6). After ILP, lacZ expression
was more homogenous and was observed around tumor-
associated vessels. Moreover, lacZ-positive cells were
found in several areas of the tumor, with a preferential
location in the viable rim. Routine examination of the nu-
merous histologic slides of tumors after both ILP and intra-
tumoral injection did not show large numbers of inflamma-
tory cells surrounding the transfected cells.
DISCUSSION
To compete with conventional modalities, anticancer
gene therapy should be both effective and safe.2 The first
requirement implies the use of viral or nonviral vector
systems that guarantee efficient gene transfer, in addition to
the application of promoters that offer appropriate expres-
sion of the desired genes. For safety, tissue specificity of
gene expression is essential, because expression of trans-
fected genes in organs other than tumor tissue may cause
potentially dangerous complications. Tissue specificity may
be accomplished at the level of gene transfer by vector
targeting, which necessitates the use of ligands or antibodies
that can be conjugated to both viral and nonviral vector
systems.2 Ligands can target a vector system to specific
tumor cell types by interacting with receptors that are ex-
clusively present on the surface of these target cells. Various
ligands have been used for vector targeting to tumor cells,
including folate, asialo-orosomucoid, and epidermal growth
factor, allowing for tumor-specific gene delivery in ovarian
cancer, hepatocellular carcinoma, and lung cancer, respec-
tively.16,17 Apart from targeted vector delivery, tumor-spe-
cific gene expression can be achieved with the use of
tumor-specific promoters such as those for carcinoembry-
onic antigen and human surfactant protein A, which are
activated only in the nuclei of tumor cells containing these
substances.18,19
The most widely applied gene transfer vectors, derived
from retroviruses or adenoviruses as well as standard pro-
moters, do not generate tumor-specific gene expression. In
the present study, systemic administration of adenoviral
vectors carrying the luciferase marker gene did not result in
significant tumor tissue expression, as was expected. The
Figure 5. Organ specificity of gene delivery 48 hours after systemic
intravenous administration using 1 3 109 infectious units IG.Ad.CMV.
Luc in WagRij rats (n 5 3). Mean luciferase activity (6SEM) was signif-
icantly greater in spleen and liver tissue compared with all other organs
(P , .005).
Figure 6. Adenovirus-mediated lacZ gene transfer to BN-175 soft tis-
sue sarcoma in rats. Blue staining represents cells actively expressing
b-gal 48 hours after treatment with 1 3 109 infectious units IG.Ad.CMV.
LacZ. After intratumoral injection, blue staining was found only around
the needle track and not in other parts of the tumor (A). After isolated
limb perfusion, lacZ gene transfer was demonstrated in various parts of
the tumor, including tumor-associated vessels (B) and the viable rim of
the tumor (C).
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predominant expression of luciferase was demonstrated in
spleen and liver tissue. Gene uptake in tumor tissue was low
and comparable to that of other organs, such as heart and
lung. These observations confirm recommendations by
other authors who advise against using systemically admin-
istered anticancer gene therapy for clinical trials unless
tissue-specific vector systems are included.2
Apart from systemic delivery, a catheter into the tumor
vasculature can be used to administer recombinant viruses.
Regional infusion of a target organ has been explored for
lung,20 liver,21 and brain,22 and effective viral-mediated
gene transfer has been demonstrated. In the present study,
gene transfer of adenoviral vectors after intraarterial infu-
sion was remarkably ineffective and was not superior to
systemic intravenous administration. The observed low
gene expression might be explained by the fact that there is
only a single passage of a small fraction of the administered
adenoviral vectors through the tumor vasculature. The vast
majority of adenoviral vectors bypass the tumor and disap-
pear in the normal vessels of the hind limb to end up in the
systemic circulation.
In principle, the simplest route of tumor-specific gene
delivery is local administration of vectors into tumors by
direct injection; this has been successfully performed in
subcutaneous malignancies23 and brain gliomas,24 the latter
with stereotactic guidance. The present experiments dem-
onstrated that intratumoral injection of adenoviral vectors
resulted in an efficient transfer of luciferase genes to tumor
cells. However, localization studies demonstrated that the
lacZ-positive tumor cells were confined to the injection site
in the tumor (needle track staining). With the ILP technique,
an extremity can be exposed to high drug concentrations for
various periods of time. Higher tissue uptake may result, as
has been demonstrated for melphalan.25,26 Moreover, the
ILP technique allows a washout procedure to remove non-
bound drug, thereby minimizing systemic contamination
after recirculation. In previous studies using tumor necrosis
factor and melphalan, we demonstrated an almost leakage-
free isolated system in the hind limb of the rat.13 This
sarcoma-bearing rat model closely mimics the clinical sit-
uation and can be used as a preclinical model for pharma-
cokinetic studies and antitumor responses. In the present
study, ILP of adenoviral vectors carrying the luciferase
marker gene resulted in a significantly higher luciferase
activity in the tumor than after systemic or regional admin-
istration, indicating an efficient gene transfer using this
technique. Intratumoral luciferase activity increased with
longer durations of perfusion, indicating the importance of
repeated passages of the adenoviral vectors for tumor cell
infection. Moreover, gene delivery using ILP showed a
homogeneous lacZ gene transfer around tumor-associated
vessels and in the viable rim of the tumor, in contrast to the
expression limited only around the needle track, as seen
after intratumoral administration.
The efficacy of adenoviral-mediated gene delivery has
previously been demonstrated in other isolated perfusion
settings, including isolated liver perfusion and isolated lung
perfusion.27,28 In these studies, no tumor was included in the
isolated circuit, so it is unknown whether there was prefer-
ential transfection of tumor cells in relation to other cell
types in the perfused circuit. The current quantitative anal-
ysis of luciferase activity in the perfused limb clearly dem-
onstrates a higher uptake of luciferase genes by tumor cells
compared with muscle tissue. This might be explained by
the fact that normal muscle tissue is inert, and the muscle
vasculature has a normal endothelial lining, in contrast to
the rapidly dividing cells and leaky vasculature in tumor
tissue. Moreover, luciferase activity in systemic organs was
low because a nearly leakage-free circuit is obtained during
ILP, and a washout procedure is performed after ILP to
remove unbound viruses before the limb is enclosed to the
circulation.
The concept of using ILP for tumor-specific gene transfer
was recently explored by Milas et al,29 who demonstrated
efficient gene delivery in tumor tissue by means of an
isolated limb perfusion model in the rat using an adenovirus
Ad.LacZ. Systemic leakage was, however, not directly
quantified by measuring marker gene activity, as in the
present study, but with the help of radioactively labeled red
blood cells. Moreover, the efficiency and tumor specificity
of adenoviral-mediated gene delivery by ILP were not quan-
titatively compared with other methods of administration.
In conclusion, our results indicate that in sarcoma-bear-
ing rats, delivery of adenoviral vectors by ILP is effective
and reproducible. Consequently, ILP might be useful for
safe, efficient, transvascular, and tumor-specific delivery of
recombinant adenoviruses carrying various therapeutic gene
constructs, including genes encoding for cytokines, angio-
genesis inhibitors, and suicide genes, to enhance tumor
control. We recently demonstrated that interleukin (IL)-3b
gene therapy by ILP was effective in the treatment of
ROS-1 and BN-175 sarcoma, whereas intratumoral injec-
tions appeared not to be effective.30 Replacement of genes
to increase sensitivity for tumor necrosis factor (e.g.,
EMAP-II) is another promising therapeutic option to in-
crease responses to tumor necrosis factor/melphalan perfu-
sion.31 Preclinical studies are ongoing to explore these
possibilities in limb and organ perfusion settings, which
may ultimately prove beneficial to cancer patients.
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Discussion
PROF. B. JEPPSSON (Malmo¨, Sweden): I guess your aim is that
you want to avoid the complications that we already have seen
when you transfer cell systems that we do not want to transfer. My
guess is also that you fairly soon want to go on to patients. You
showed us the time–response curve, which was also in the abstract.
What do you think will be the optimal time, in a patient, when you
want to isolate the limb? That is my first question. I also wonder
if you have any idea of the amount of gene you want to transfer to
have any clinical efficiency with your system. And finally, you
also showed us that you did not have any systemic leak. Was that
also estimated a long time after the end of the perfusion?
DR. W. DE ROOS (Rotterdam, The Netherlands): To answer your
last question first, we did not have much time to evaluate the
long-term systemic leakage because the rats were sacrificed after 2
days, so the results on systemic leakage represent the situation at
48 hours after perfusion. In answer to the second question, we have
performed this kind of research. Recently we performed studies in
which we used the gene encoding for the cytokine IL-3b in this rat
model. We compared the administration of adenoviral vectors by
isolated limb perfusion to intratumoral injection, systemic (intra-
venous) administration, and regional (intraarterial) infusion. Only
after isolated limb perfusion was a significant antitumor response
of the IL-3b gene observed. Moreover, we demonstrated that this
effect was dose-dependent. However, on this basis I cannot predict
the concentration of adenoviral vectors that would have to be used
in humans. Your first question is about the perfusion time. Our
data suggests that the adenovirus infects the cells very quickly, so
there is no need to prolong the perfusion time beyond 15 minutes
because you do not get a significantly higher uptake by the tumor
after 30 minutes of perfusion.
PROF. P. KINNAERT (Brussels, Belgium): My question is related
to the safety of the procedure. How can you be sure that the genetic
information of the transfected cancer cells will not be transmitted
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later on to the surrounding tissues? How do you protect the
medical personnel?
DR. DE ROOS: To answer your first question on the construction
of the virus factor, what you do is remove the pathological genes
from the virus and replace them with the therapeutic gene that you
need. In this removal of the pathological genes, you remove the
capacity of the virus to infect again. By using this isolated tech-
nique, you minimize the infection of other tissues. That is the
whole issue of the isolated perfusion.
PROF. B. KREMER (Kiel, Germany): Can you speculate on the
tumor specificity of the virus? Is it transferred to the tumor and not
to the surrounding tissue because of the more activated cell divi-
sion of endothelial cells in the tumor vessels?
DR. DE ROOS (Closing Discussion): Tumor-associated vessels
differ from normal vessels. We speculate that the endothelial lining
of tumor vasculature is more penetrable for adenoviral vectors in
comparison to vasculature in normal tissue—e.g., muscle tissue.
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